ReviewTrends in pharmacological sciences2020
Beyond Deterministic Models in Drug Discovery and Development.
Review in Trends in pharmacological sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- From bench to bedside: Overcoming translational hurdles in nanoparticle research with pharmacokinetic modeling.Bioengineering & translational medicine · 2026Review
- Stochastic Differential Equations (SDEs) in NONMEM for Probing Population Pharmacokinetic Model Misspecification: Diagnostic Utility, Practical Considerations, and Future Directions.The AAPS journal · 2026Article
- A Machine Learning Platform for Imputing Missing Critical Quality Attributes in Pharmaceutical Development.The AAPS journal · 2026Article
- Interpretable Two-Stage Machine Learning for Early and Full Drug Release Prediction in PLGA Microspheres.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Blood-glucose Profile Evaluation with a Model-based Approach using Continuous Glucose Monitoring Data.The AAPS journal · 2026Article
- Modelling Immune Dynamics in Locally Advanced MSI-H/dMMR Colorectal Cancer with Neoadjuvant Pembrolizumab Treatment: From Differential Equations to an Agent-Based Framework.Bulletin of mathematical biology · 2026Article
- Machine Learning Predicts Drug Release Profiles and Kinetic Parameters Based on Tablets' Formulations.The AAPS journal · 2025Article
- Stochastic pharmacodynamics of a heterogeneous tumour-cell population.Journal of pharmacokinetics and pharmacodynamics · 2025Article
- Structural and practical identifiability analysis in bioengineering: a beginner's guide.Journal of biological engineering · 2024Article
- Calibration of agent based models for monophasic and biphasic tumour growth using approximate Bayesian computation.Journal of mathematical biology · 2024Article
- Machine learning models to accelerate the design of polymeric long-acting injectables.Nature communications · 2023Article
- Optimizing Clinical Outcomes Through Rational Dosing Strategies: Roles of Pharmacokinetic/Pharmacodynamic Modeling Tools.Open forum infectious diseases · 2022Review
- Two heads are better than one: current landscape of integrating QSP and machine learning : An ISoP QSP SIG white paper by the working group on the integration of quantitative systems pharmacology and machine learning.Journal of pharmacokinetics and pharmacodynamics · 2022Review
- A stochastic mixed effects model to assess treatment effects and fluctuations in home-measured peak expiratory flow and the association with exacerbation risk in asthma.CPT: pharmacometrics & systems pharmacology · 2022Article
- Factor Xa inhibitors: critical considerations for clinical development and testing.Journal of thrombosis and thrombolysis · 2021Review
- Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The model-informed drug discovery and development paradigm is now well established among the pharmaceutical industry and regulatory agencies. This success has been mainly due to the ability of pharmacometrics to bring together different modeling strategies, such as population pharmacokinetics/pharmacodynamics (PK/PD) and systems biology/pharmacology. However, there are promising quantitative approaches that are still seldom used by pharmacometricians and that deserve consideration. One such case is the stochastic modeling approach, which can be important when modeling small populations because random events can have a huge impact on these systems. In this review, we aim to raise awareness of stochastic models and how to combine them with existing modeling techniques, with the ultimate goal of making future drug-disease models more versatile and realistic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.